Treatment of prostate cancer

Prostate cancer is the commonest cancer in men, with more than 70,000 new cases annually in France. This is usually a slowly developing cancer. It can be completely silent or may be the cause of urinary symptoms such as difficulty in passing urine or frequency of micturition.

Gustave Roussy is a non-profit making private health establishment with a public role.
As a Cancer Centre, its status derives from Directive n° 45-2221 of the 1st October 1945, modified by Directive n° 2005-406 of the 2nd May 2005 and by the "HPST" Law of 21st July 2009 on hospital reform with a bearing on patients, health and local authorities. 

Gustave Roussy is a member of Unicancer, an organisation to which all French Cancer Centres belong.

International Thoracic Cancer Center Staff

Gustave Roussy

• Fabrice Barlesi, General Director of Gustave Roussy, medical oncologist
• David Planchard, thoracic oncologist, chairman of the thoracic cancer commitee of Gustave Roussy and president of the International Thoracic Cancer Center
• Benjamin Besse, medical oncologist, director of clinical research at Gustave Roussy

Lung cancer treatment

Patients with lung, pleural or mediastinal cancer may be offered different treatments, depending on the type of cancer and its spread or stage at the time of diagnosis. Treatments may be combined during therapy.

Local treatments

Surgery

Management of lung cancer

• Adult bronchopulmonary cancers: non-small cell and small cell carcinomas
• Pleural tumours: mesothelioma and others
• Mediastinal tumours: thymoma and others
• Pleuropulmonary metastases requiring local treatment (committee-coordinated management depending on the primary tumour site)

The International Thoracic Cancer Centre

History of the Institute

Professor Gustave Roussy was a specialist in pathological anatomy. In 1921 he established the first outpatient service for patients with cancer in Jean L’Hermitte’s department at the Paul-Brousse Hospital in Villejuif. Even at that time his intention was to combine patient care with research and teaching.

Traitements des cancers ORL

Le traitement du cancer ORL est issu d’une décision multidisciplinaire. Il est réalisé en fonction de la localisation de la tumeur, de son extension (taille, rapports avec les structures avoisinantes, ganglions et localisations secondaires) et de l'existence d'autres maladies chez le patient.

Leading Cancer Centre in Europe, Gustave Roussy is ranked #4 world's best oncology hospital according to Newsweek magazine and the first one outside the United States. The institute treats patients with all types of cancer at any age and is expert in the treatment of rare and complex tumours.

We place innovation at the heart of a human, scientific and technological revolution in the fight against cancer. 

Dermatology Committee

Prof. Caroline Robert, Chairman
Dr Emilie Routier
Dr Cristina Libenciuc

Senior oncologists

Dr Sarah Faouzi
Dr Pauline Lepesant
Dr Feyrouz Toukal
Dr Madona Sakkal
Dr Koreissi Tall
Dr Bertrand Bachollet
Dr Hélène Bocquet
Dr Richard Encoua
Dr Marie Reigneau
Dr Béatrix Reynaud-Mendel
Dr Marina Thomas
Dr Florence Weill

Traitement du mélanome

Chirurgie

Le traitement est chirurgical : une exérèse large, dont les marges sont fonction de l'épaisseur du mélanome. Le mélanome est retiré dans un premier temps ; une fois les résultats de l'analyse histologique obtenus (et notamment de l'épaisseur du mélanome), la reprise d'exérèse avec des marges saines adaptées est réalisée.